

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

**INSIDE INFORMATION  
UPDATE ON THE POTENTIAL ISSUANCE OF SHARES  
BY CR PHARMACEUTICAL COMMERCIAL**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Reference is made to the announcement dated 30 October 2023 (the “**Announcement**”) made by China Resources Pharmaceutical Group Limited (the “**Company**”) in relation to the potential issuance of shares by China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司) (“**CR Pharmaceutical Commercial**”), a wholly-owned subsidiary of the Company (the “**Potential Issuance**”). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

## **COMMENCEMENT OF BIDDING PROCESS FOR THE POTENTIAL ISSUANCE BY CR PHARMACEUTICAL COMMERCIAL**

The Board hereby announces that, on 27 November 2023, the bidding process in relation to the Potential Issuance (the “**Bidding Process**”) commenced via the China Beijing Equity Exchange. CR Pharmaceutical Commercial has published an application form for disclosure of information for capital raising on 27 November 2023 in relation to the Bidding Process (the “**Application**”) on the website of the China Beijing Equity Exchange.

As stated in the Application, it is proposed that CR Pharmaceutical Commercial will issue shares to not more than 12 investors (with joint venture being counted as one investor) via the China Beijing Equity Exchange, and following the completion of the Potential Issuance, such investors will hold no less than 15% and no more than 25% of the enlarged number of issued shares of CR Pharmaceutical Commercial. The subscription price for the Potential Issuance shall not be lower than the asset appraisal value filed by CR Pharmaceutical Commercial, and shall be subject to the final bidding results. Furthermore, Beijing Pharmaceutical Group Company Limited (北京醫藥集團有限責任公司) and China Resources Pharmaceutical Investment Company Limited (華潤醫藥投資有限公司), the existing shareholders of CR Pharmaceutical Commercial, may decide whether to concurrently participate in this Potential Issuance by way of non-public issuance depending on the capital raising conditions; and in event that they concurrently participate in this Potential Issuance, their subscription and investment amount shall not exceed RMB1 billion and their subscription price shall be the same as that of the external investors. The final size and terms and conditions of the Potential Issuance will be subject to the finalization of the subscription agreement(s) to be entered into with the subscriber(s) under the Potential Issuance. The proposed use of proceeds under the Potential Issuance will be for funding future mergers and acquisitions, establishing logistics infrastructure, and/or repaying outstanding banking facilities.

Full text of the Application is available on the website of the China Beijing Equity Exchange at [www.cbex.com.cn](http://www.cbex.com.cn).

The Board wishes to emphasize that no binding agreement with respect to the Potential Issuance has been entered into by CR Pharmaceutical Commercial as at the date of this announcement, and there is no assurance that any definitive transaction with respect to the Potential Issuance will materialize. The Company will make further announcement(s) in compliance with the Listing Rules and/or Part XIVA of the SFO as and when appropriate or required.

**As CR Pharmaceutical Commercial may or may not enter into a binding agreement with respect to the Potential Issuance, and even if it decides to do so, the Potential Issuance may be subject to fulfilment of closing conditions and may or may not proceed to completion for various reasons. Accordingly, shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

*For ease of reference, the names of the PRC established companies or entities have been included in this announcement in both the Chinese and English languages, and in the event of any inconsistency, the Chinese version shall prevail.*

By order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Hong Kong, 27 November 2023

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*